Disease Introduction
Alopecia areata, commonly known as "spot baldness," is an autoimmune, non-scarring hair loss characterized by the sudden appearance of round/oval bald patches on the scalp. In severe cases, it can progress to total or diffuse alopecia and is often associated with mental stress, genetics, and immune disorders. Treatment has evolved from topical medications/injections to oral targeted therapies, with moderate to severe cases achieving near-complete hair regrowth through JAK inhibitors.
Cutting-edge high-precision diagnostic and treatment technologies
- Oral JAK inhibitors : Baricitinib (Ailemin) is an oral JAK1/2 inhibitor. In March 2023, it was approved by the NMPA for the systemic treatment of severe alopecia areata in adults. It is the first targeted systemic treatment drug for severe alopecia areata in China. The BRAVE-AA-PEDS Phase III study showed that adolescent patients could achieve almost complete scalp hair regrowth after one year of treatment.
- Highly selective JAK3 inhibitor : Litexitinib (Lefeno) is a JAK3/TEC dual pathway inhibitor. In October 2023, it was approved by the NMPA for the treatment of severe alopecia areata in adolescents aged 12 years and older and adults. It is the only alopecia areata drug in China to receive "breakthrough therapy designation".
- New deuterated JAK inhibitor : deuruxolitinib (LEQSELVI) is a deuterated JAK1/2 inhibitor. It was approved by the US FDA in July 2024 for the treatment of severe alopecia areata in adults. It is a new generation of JAK inhibitors in the field of alopecia areata.
- Topical pan-JAK inhibitors : delgocitinib is a topical pan-JAK (JAK1/2/3/TYK2) inhibitor that has been approved in Japan for atopic dermatitis. Several clinical trials for its indication in alopecia areata have been registered and carried out in China, providing a non-oral local targeted option for mild to moderate alopecia areata.
